The genetic variation of CCR5, CXCR4 and SDF-1 in three Chinese ethnic populations

Infection, Genetics and Evolution

Volumn 12, Issue 5, 2012, Pages 1072-1078

  Liu, Yanyan ^a   Liu, Feng Liang ^b   He, Yanqin ^c   Li, Liming ^a   Li, Shilin ^a   Zheng, Yong Tang ^b   Wang, Hongyan ^a   Gong, Xiaohong ^a  

^a FUDAN UNIVERSITY   (China)

^b KUNMING INSTITUTE OF ZOOLOGY   (China)

^c SHANXI NORMAL UNIVERSITY   (China)

Author keywords

CCR5; CXCR4; HIV; Polymorphism; SDF 1

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; STROMAL CELL DERIVED FACTOR 1;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CCR5 GENE; CHINESE; CONTROLLED STUDY; CXCR4 GENE; DISEASE COURSE; ETHNIC DIFFERENCE; GENE; GENE FREQUENCY; GENE IDENTIFICATION; GENE LINKAGE DISEQUILIBRIUM; GENE MAPPING; GENETIC ANALYSIS; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HAN CHINESE; HAPLOTYPE; HUMAN; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; MONGOL CHINESE; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; OPEN READING FRAME; POPULATION GENETICS; POPULATION RESEARCH; PRIORITY JOURNAL; PROTEIN FUNCTION; REGULATOR GENE; SDF1 GENE; SEQUENCE ANALYSIS; UYGHUR CHINESE;

ADULT; ALLELES; ASIAN CONTINENTAL ANCESTRY GROUP; CHEMOKINE CXCL12; CHINA; ETHNIC GROUPS; HAPLOTYPES; HUMANS; INDEL MUTATION; LINKAGE DISEQUILIBRIUM; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, CCR5; RECEPTORS, CXCR4;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84860379966     PISSN: 15671348     EISSN: 15677257     Source Type: Journal    
DOI: 10.1016/j.meegid.2012.03.009     Document Type: Article

References (26)

1. Benkirane M., Jin D.Y., Chun R.F., Koup R.A., Jeang K.T. Mechanism of transdominant inhibition of CCR5-mediated HIV-1 infection by ccr5delta32. J. Biol. Chem. 1997, 272:30603-30606.
2. Berger E.A., Murphy P.M., Farber J.M. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu. Rev. Immunol. 1999, 17:657-700.
3. Carrington M., Kissner T., Gerrard B., Ivanov S., O'Brien S.J., Dean M. Novel alleles of the chemokine-receptor gene CCR5. Am. J. Genet. 1997, 61:1261-1267.
4. Chu T.X., Levy J.A. Injection drug use and HIV/AIDS transmission in China. Cell Res. 2005, 15:865-869.
5. Connor R.I., Sheridan K.E., Ceradini D., Choe S., Landau N.R. Change in coreceptor use correlates with disease progression in HIV-1 infected individuals. J. Exp. Med. 1997, 185:621-628.
6. Deng H., Liu R., Ellmeier W., Choe S., Unutmaz D., Burkhart M., Di Marzio P., Marmon S., Sutton R.E., Hill C.M., Davis C.B., Peiper S.C., Schall T.J., Littman D.R., Landau N.R. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996, 381:661-666.
7. Feng Y., Broder C.C., Kennedy P.E., Berger E.A. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996, 272:872-877.
8. Galvani A.P., Novembre J. The evolutionary history of the CCR5-Delta32 HIV-resistance mutation. Microbes Infect. 2005, 7:302-309.
9. Gonzalez E., Bamshad M., Sato N., Mummidi S., Dhanda R., Catano G., Cabrera S., McBride M., Cao X.H., Merrill G., O'Connell P., Bowden D.W., Freedman B.I., Anderson S.A., Walter E.A., Evans J.S., Stephan K.T., Clark R.A., Tyagi S., Ahujia S.S., Dolan M.J., Ahuja S.K. Race-specific HIV-1 disease-modifying effects associated with CCR5 haplotypes. Proc. Natl. Acad. Sci. USA 1999, 96:12004-12009.
10. Gonzalez E., Dhanda R., Bamshad M., Mummidi S., Geevarghese R., Catano G., Anderson S.A., Walter E.A., Stephan K.T., Hammer M.F., Mangano A., Sen L., Clark R.A., Ahuja S.S., Dolan M.J., Ahuja S.K. Global survey of genetic variation in CCR5, RANTES, and MIP-1alpha: impact on the epidemiology of the HIV-1 pandemic. Proc. Natl. Acad. Sci. USA 2001, 98:5199-5204.
11. Ioannidis J.P., Rosenberg P.S., Goedert J.J., Ashton L.J., Benfield T.L., Buchbinder S.P., Coutinho R.A., Eugen-Olsen J., Gallart T., Katzenstein T.L., Kostrikis L.G., Kuipers H., Louie L.G., Mallal S.A., Margolick J.B., Martinez O.P., Meyer L., Michael N.L., Operskalski E., Pantaleo G., Rizzardi G.P., Schuitemaker H., Sheppard H.W., Stewart G.J., Theodorou I.D., Ullum H., Vicenzi E., Vlahov D., Wilkinson D., Workman C., Zagury J.F., O'Brien T.R. Effects of CCR5-Delta32, CCR2-64I, and SDF-1 3'A alleles on HIV-1 disease progression: an international meta-analysis of individual-patient data. Ann. Intern. Med. 2001, 135:782-795.
12. Ma Q., Jones D., Borghesani P.R., Segal R.A., Nagasawa T., Kishimoto T., Bronson R.T., Springer T.A. Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4 and SDF-1 deficient mice. Proc. Natl. Acad. Sci. USA 1998, 95:9448-9453.
13. McDermott D.H., Zimmerman P.A., Guignard F., Kleeberger C.A., Leitman S.F., Murphy P.M. CCR5 promoter polymorphism and HIV-1 disease progression. Lancet 1998, 352:866-870.
14. Mellado M., Rodríguez-Frade J.M., Vila-Coro A.J., de Ana A.M., Martínez-A C. Chemokine control of HIV infection. Nature 1999, 400:723-724.
15. Meyer L., Magierowska M., Hubert J.B., Rouzioux C., Deveau C., Sanson F., Debre P., Delfraissy J.F., Theodorou I. Early protective effect of CCR-5 delta 32 heterozygosity on HIV-1 disease progression: relationship with viral load. AIDS 1997, 11:F73-F78.
16. Michael N.L., Chang G., Louie L.G., Mascola J.R., Dondero D., Birx D.L., Sheppard H.W. The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression. Nat. Med. 1997, 3:338-340.
17. Mummidi S., Ahuja S.S., Gonzalez E., Anderson S.A., Santiago E.N., Stephan K.T., Craig F.E., O'Connell P., Tryon V., Clark R.A., Dolan M.J., Ahuja S.K. Genealogy of the CCR5 locus and chemokine system gene variants associated with altered rates of HIV-1 disease progression. Nature 1998, 4:786-793.
18. Oberlin E., Amara A., Bachelerie F., Bessia C., Virelizier J.L., Arenzana-Seisdedos F., Schwartz O., Heard J.M., Clark-Lewis L., Legler D.F., Loetscher M., Baggiolini M., Moser B. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line adapted HIV-1. Nature 1996, 382:833-835.
19. Picton A.C., Paximadis M., Tiemessen C.T. Genetic variation within the gene encoding the HIV-1 CCR5 coreceptor in two South African populations. Infect Genet. Evol. 2010, 10:487-494.
20. Premack B.A., Schall T.J. Chemokine receptors: gateways to inflammation and infection. Nat. Med. 1996, 2:1174-1178.
21. Princen K., Schols D. HIV chemokine receptor inhibitors as novel anti-HIV drugs. Cytokine Growth Factor Rev. 2005, 16:659-677.
22. Telenti A., Goldstein D.B. Genomics meets HIV-1. Nat. Rev. Microbiol. 2006, 4:865-873.
23. Theodorou I., Meyer L., Magierowska M., Katlama C., Rouzioux C. HIV-1 infection in an individual homozygous for CCR5 delta 32. Lancet 1997, 349:1219-1220.
24. Venkatesan S., Petrovic A., Van Ryk D.l., Locati M., Weissman D., Murphy PM. Reduced cell surface expression of CCR5 in CCR5DELTA32 heterozygotes is mediated by gene dosage, rather than by receptor sequestration. J. Biol. Chem. 2002, 277:2287-2301.
25. Williamson C., Loubser S.A., Brice B., Joubert G., Smit T., Thomas R., Visaqie M., Cooper M., van der Ryst E. Allelic frequencies of host genetic variants influencing susceptibility to HIV-1 infection and disease in South African populations. AIDS 2000, 14:449-451.
26. Zou Y.R., Kottmann A.H., Kuroda M., Taniuchi l., Littman D.R. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 1998, 393:595-599.